Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CANF NASDAQ:ERNA NASDAQ:HOOK NASDAQ:NEUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$1.04-1.0%$1.06$0.98▼$4.69$3.66M1.11238,476 shs37,016 shsERNAErnexa Therapeutics$1.98-2.9%$2.59$1.75▼$34.35$14.57M5.3200,633 shs64,203 shsHOOKHOOKIPA Pharma$1.14$1.38$0.72▼$6.68$13.90M0.8982,930 shs185,284 shsNEUPNeuphoria Therapeutics$7.45-0.5%$6.66$2.12▼$12.55$14.01M0.535,541 shs12,813 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma0.00%0.00%-1.90%-16.53%-77.00%ERNAErnexa Therapeutics0.00%+1.02%-19.18%-26.17%-93.86%HOOKHOOKIPA Pharma0.00%-4.20%-11.63%+52.00%-82.24%NEUPNeuphoria Therapeutics0.00%-3.12%+9.56%+43.27%+744,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCANFCan-Fite BioPharma2.4619 of 5 stars3.53.00.00.00.00.01.3ERNAErnexa Therapeutics0.2759 of 5 stars0.03.00.00.00.61.70.0HOOKHOOKIPA Pharma2.8776 of 5 stars3.25.00.00.01.81.70.6NEUPNeuphoria Therapeutics1.3078 of 5 stars3.50.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANFCan-Fite BioPharma 3.00Buy$14.001,252.66% UpsideERNAErnexa Therapeutics 0.00N/AN/AN/AHOOKHOOKIPA Pharma 2.33Hold$4.50294.74% UpsideNEUPNeuphoria Therapeutics 3.00Buy$21.00181.88% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANFCan-Fite BioPharma$674K5.44N/AN/A$1.76 per share0.59ERNAErnexa Therapeutics$580K25.13N/AN/A$0.50 per share3.96HOOKHOOKIPA Pharma$43.95M0.32N/AN/A$4.25 per share0.27NEUPNeuphoria Therapeutics$10K1,400.60N/AN/A$15.85 per share0.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/AERNAErnexa Therapeutics-$44.54M-$8.31N/A∞N/A-7,652.75%N/A-285.71%8/12/2025 (Estimated)HOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%8/6/2025 (Estimated)NEUPNeuphoria Therapeutics-$15.49MN/A0.00N/AN/AN/AN/AN/A9/29/2025 (Estimated)Latest CANF, HOOK, NEUP, and ERNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025HOOKHOOKIPA Pharma-$0.64N/AN/AN/AN/AN/A5/20/2025Q3 2025NEUPNeuphoria Therapeutics-$0.47$6.55+$7.02$6.55N/A$15.00 million5/15/2025Q1 2025HOOKHOOKIPA Pharma-$0.61-$1.23-$0.62-$1.23$3.38 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCANFCan-Fite BioPharmaN/AN/AN/AN/AN/AERNAErnexa TherapeuticsN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANFCan-Fite BioPharmaN/A2.93N/AERNAErnexa TherapeuticsN/A0.210.21HOOKHOOKIPA PharmaN/A3.613.61NEUPNeuphoria TherapeuticsN/A11.0111.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANFCan-Fite BioPharma21.00%ERNAErnexa Therapeutics70.55%HOOKHOOKIPA Pharma63.88%NEUPNeuphoria Therapeutics15.90%Insider OwnershipCompanyInsider OwnershipCANFCan-Fite BioPharma0.80%ERNAErnexa Therapeutics4.49%HOOKHOOKIPA Pharma3.30%NEUPNeuphoria Therapeutics0.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANFCan-Fite BioPharma83.54 millionN/ANot OptionableERNAErnexa Therapeutics107.36 million7.03 millionNo DataHOOKHOOKIPA Pharma16012.19 million11.79 millionOptionableNEUPNeuphoria TherapeuticsN/A1.88 million1.87 millionN/ACANF, HOOK, NEUP, and ERNA HeadlinesRecent News About These CompaniesDementia Associated with Alzheimer’s Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers | DelveInsightJuly 17, 2025 | finance.yahoo.comNEUP Neuphoria Therapeutics Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comNeuphoria Therapeutics Inc. (NEUP) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNeuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual MeetingMay 27, 2025 | globenewswire.comNeuphoria Therapeutics, Inc.: Neuphoria Provides First Quarter 2025 Business UpdatesMay 21, 2025 | finanznachrichten.deNeuphoria Provides First Quarter 2025 Business UpdatesMay 20, 2025 | globenewswire.comNeumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comNeuphoria Therapeutics provides review of 2024, highlights 2025 plansApril 16, 2025 | markets.businessinsider.comNeuphoria Provides a Review of 2024 and Highlights 2025 PlansApril 15, 2025 | globenewswire.comNeuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025March 3, 2025 | globenewswire.comNeuphoria Therapeutics Inc. to Receive $15M Milestone Payment from MerckFebruary 12, 2025 | globenewswire.comHere's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep goingFebruary 6, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCANF, HOOK, NEUP, and ERNA Company DescriptionsCan-Fite BioPharma NYSE:CANF$1.03 -0.01 (-0.96%) Closing price 07/18/2025 03:56 PM EasternExtended Trading$1.03 0.00 (-0.48%) As of 07/18/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Ernexa Therapeutics NASDAQ:ERNA$1.98 -0.06 (-2.94%) Closing price 07/18/2025 03:52 PM EasternExtended Trading$2.00 +0.02 (+0.76%) As of 07/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.HOOKIPA Pharma NASDAQ:HOOK$1.14 0.00 (0.00%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.18 +0.04 (+3.51%) As of 07/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Neuphoria Therapeutics NASDAQ:NEUP$7.45 -0.04 (-0.53%) As of 07/18/2025 03:55 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
